We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Gilead Sciences Inc | NASDAQ:GILD | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.57 | 0.88% | 65.35 | 64.98 | 65.47 | 65.56 | 64.34 | 64.78 | 7,186,810 | 22:36:16 |
From May 2022 to May 2024
By Colin Kellaher
Gilead Sciences Inc. on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of its investigational drug lenacapavir for people with multi-drug-resistant HIV.
The recommendation covers lenacapavir for the treatment of HIV-1 infection, in combination with other antiretrovirals, in adults with multi-drug resistant HIV-1 infection for whom it otherwise isn't possible to construct a suppressive anti-viral regimen, the Foster City, Calif., biopharmaceutical company said.
It expects a final decision from the European Commission, which generally follows the CHMP's advice, later this year.
The U.S. Food and Drug Administration earlier this year rejected Gilead's application seeking approval of lenacapavir due to issues related to the vials in which the drug is stored. Gilead recently said it has identified an alternative vial for lenacapavir.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
June 24, 2022 08:48 ET (12:48 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Gilead Sciences Chart |
1 Month Gilead Sciences Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
